Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the strategic acquisition of PULMOTREE, a Munich, Germany-based life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs. The acquisition is expected to accelerate the development, industrialization and commercialization of PULMOTREE's Kolibri™ Non-Propellant Liquid Inhaler (NPLI) platform.
The acquisition is intended to expand Aptar Pharma's opportunities for growth in respiratory drug delivery by adding a differentiated non-propellant platform capable of supporting the delivery of complex molecules, including biologics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.